Cell-surface Vimentin: A mislocalized protein for isolating csVimentin+CD133- novel stem-like hepatocellular carcinoma cells expressing EMT markers

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 491-496

  Mitra, Abhisek ^a   Satelli, Arun ^a   Xia, Xueqing ^a   Cutrera, Jeffrey ^a   Mishra, Lopa ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

EMT; HCC; liver cancer stem cells; metastasis

Indexed keywords

CD133 ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN; ANTIBODY; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROTEIN BINDING; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL SELECTION; CELL SURFACE; CELL SUSPENSION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; ANIMAL; CANCER STEM CELL; CELL MEMBRANE; CONFOCAL MICROSCOPY; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIGENS, CD; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; PROTEIN BINDING; SOXB1 TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VIMENTIN;

EID: 84929288972     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29382     Document Type: Article

References (24)

1. Altekruse SF, McGlynn KA, Reichman ME., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
2. El-Serag HB., Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34.
3. Carr BI., Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: S218-S224.
4. Lee TK, Castilho A, Cheung VC, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63.
5. Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-58.
6. Chuthapisith S, Eremin J, El-Sheemey M, et al. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 2010; 19: 27-32.
7. Rountree CB, Ding W, He L, et al. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 2009; 27: 290-9.
8. Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-39.
9. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-66.
10. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
11. Satelli A, Brownlee Z, Mitra A, Meng QH, Li S,. Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Molecule- and Cell-Surface Vimentin-Based Methods for Monitoring Breast Cancer Therapeutic Response. Clinical chemistry 2014.
12. Satelli A, Mitra A, Cutrera JJ, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 2015; 74: 1645-50.
13. Mitra A, Mishra L, Li S., Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol 2013; 31: 347-54.
14. Lee KD, Kuo TK, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004; 40: 1275-84.
15. Yu B, He ZY, You P, et al. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell 2013; 13: 328-40.
16. Mitra A, Ross JA, Rodriguez G, et al. Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies. J Biol Chem 2012; 287: 16596-608.
17. Nagy ZS, LeBaron MJ, Ross JA, et al. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer 2009; 8: 67.
18. Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, Mishra L, Li S,. IL-0000 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 2014; 60: 2027-39.
19. May CD, Sphyris N, Evans KW, et al. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011; 13: 202.
20. Fan QM, Jing YY, Yu GF, et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett 2014; 352: 160-8.
21. Hollier BG, Tinnirello AA, Werden SJ, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013; 73: 1981-92.
22. Chang L, Graham PH, Hao J, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013; 4: e875.
23. Li T, Fan J, Qin LX, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol 2011; 18: 1955-63.
24. Ho CM, Lee PH, Shau WY, et al. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery 2012; 151: 700-9.